RECURRENT FALLOPIAN TUBE CARCINOMA
Clinical trials for RECURRENT FALLOPIAN TUBE CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT FALLOPIAN TUBE CARCINOMA trials appear
Sign up with your email to follow new studies for RECURRENT FALLOPIAN TUBE CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Ovarian cancer vaccine shows promise in early safety trial
⭐️ VACCINE ⭐️ CompletedThis early-phase study tested a personalized vaccine made from patients' own white blood cells to treat advanced ovarian, fallopian tube, or primary peritoneal cancer. The vaccine was designed to help the immune system recognize and attack cancer cells. The main goal was to check…
Matched conditions: RECURRENT FALLOPIAN TUBE CARCINOMA
Phase: EARLY_PHASE1 • Sponsor: Mayo Clinic • Aim: ⭐️ VACCINE ⭐️
Last updated May 22, 2026 14:03 UTC
-
New hope for ovarian cancer? drug combo shows promise in trial
Disease control CompletedThis study tested a new drug combination (relacorilant plus nab-paclitaxel) in 178 women with ovarian, fallopian tube, or peritoneal cancer that came back after platinum-based treatment. The goal was to see if the combo could delay cancer growth better than nab-paclitaxel alone. …
Matched conditions: RECURRENT FALLOPIAN TUBE CARCINOMA
Phase: PHASE2 • Sponsor: Corcept Therapeutics • Aim: Disease control
Last updated May 26, 2026 06:03 UTC
-
Targeted radiation shows promise for recurring gynecologic cancers
Disease control CompletedThis early-stage study tested a precise type of radiation called stereotactic body radiation therapy (SBRT) in 15 women whose ovarian or uterine cancer had returned in a limited area. The goal was to find the safest dose and see if it could control the cancer without major side e…
Matched conditions: RECURRENT FALLOPIAN TUBE CARCINOMA
Phase: PHASE1 • Sponsor: University of Colorado, Denver • Aim: Disease control
Last updated May 26, 2026 06:01 UTC
-
Immunotherapy combo shows promise for tough ovarian cancer
Disease control CompletedThis study tested two immunotherapy drugs, durvalumab and tremelimumab, in 100 people with ovarian, fallopian tube, or peritoneal cancer that stopped responding to platinum-based chemo. The goal was to see if giving the drugs together or one after the other worked better at contr…
Matched conditions: RECURRENT FALLOPIAN TUBE CARCINOMA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 26, 2026 05:49 UTC